Transcatheter Aortic Valve Replacement Market Expected to Achieve 14% CAGR by 2029: Growth Forecast Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Transcatheter Aortic Valve Replacement Market Size By 2025?
The market size for transcatheter aortic valve replacement has been expanding quite swiftly in the recent times. It is expected to rise from a value of $5.19 billion in 2024 to $5.91 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.9%. Factors contributing to the surge during this historical period include the growing incidence of aortic regurgitation, rising occurrence of cardiovascular diseases, amplified patient inclination towards minimally invasive treatments, worldwide growth of TAVR procedures, and advantageous reimbursement policies.

How Big Is the Transcatheter Aortic Valve Replacement Market Size Expected to Grow by 2029?
In the ensuing years, we anticipate a swift expansion in the market size of transcatheter aortic valve replacement, which is projected to escalate to $9.97 billion by 2029 with a compound annual growth rate (CAGR) of 14.0%. The uptrend during the forecast period can be credited to the surge in aortic stenosis cases, the trending preference for minimally invasive procedures, broadening of indications for TAVR procedures, agreeable reimbursement policies, and growing recognition of TAVR as a potential therapeutic pathway. Key trends predicted to shape the forecast period are the continuous progression in device technology, growing incidence of cardiovascular diseases, global proliferation of TAVR procedures, a growing older population, and an increase in healthcare expenditures.

View the full report here:
https://www.thebusinessresearchcompany.com/report/transcatheter-aortic-valve-replacement-global-market-report

Which Key Market Drivers Powering Transcatheter Aortic Valve Replacement Market Expansion and Growth?
The escalating incidence of aortic stenosis is a primary catalyst propelling the advancement of the transcatheter aortic valve replacement industry. Aortic stenosis denotes a healthcare condition where there is a constriction of the heart's aortic valve. This ailment can be effectively managed with transcatheter aortic valve replacement (TAVR), a less invasive substitute to surgical aortic valve replacement (SAVR) that assists in reinstating blood circulation and diminishing the signs and symptoms of aortic valve stenosis. For example, as per information divulged by the American Heart Association in May 2024, a non-profit organization based in the US, aortic stenosis impacts over 12% of elderly Americans and is prevalent among individuals aged 65 and above. If neglected, this condition can precipitate heart failure and might prove fatal. In addition, in March 2023, as per a report issued by the National Institute for Health and Care Excellence (NICE), a public organization in the UK, close to 1.5% of UK individuals over 55, approximately 300,000, are afflicted with severe aortic stenosis, and nearly 200,000 exhibit symptomatic disease necessitating treatment, leading to over 380,000 individuals on cardiac waiting lists as of March 2023. Consequently, the escalating prevalence of aortic stenosis is fueling the transcatheter aortic valve replacement industry.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12031&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Transcatheter Aortic Valve Replacement Market?
Promoting product innovation is a major trend in the transcatheter aortic valve replacement (TAVR) market. Firms in the TAVR sector are strategizing on creating innovative and technologically advanced solutions to enhance their market standing. For example, in May 2024, Edwards Lifesciences, a medical technology firm based in the US, introduced the Sapien 3 Ultra Resilia valve in Europe. It marks the only TAVR system incorporating the company's Resilia tissue technology. This groundbreaking technology, which aims to prolong the valve's lifespan, employs bovine pericardial tissue infused with anti-calcification treatments. Through the integration of this calcium-inhibiting technology, the Resilia system addresses structural valve degradation, a primary reason for reintervention post valve replacement.

What Are the Emerging Segments in the Transcatheter Aortic Valve Replacement Market?
The transcatheter aortic valve replacement market covered in this report is segmented -

1) By Product: Self-Expandable Transcatheter Aortic Valves, Balloon-Expandable Transcatheter Aortic Valves, Mechanically Expanded Transcatheter Aortic Valves
2) By Material: Valve Frame Material, Valve Leaflet Material
3) By Procedure: Transfemoral Implantation, Transapical Implantation, Transaortic Implantation
4) By Application: Aortic Stenosis, Aortic Regurgitation, Other Applications
5) By End-User: Hospitals, Independent Cardiac Catheterization Labs, Ambulatory Surgical Centers, Other End-Users

Subsegments:
1) By Self-Expandable Transcatheter Aortic Valves: Nitinol Frame Self-Expandable Valves, Polyester and Polyurethane Coated Valves
2) By Balloon-Expandable Transcatheter Aortic Valves: Balloon-Expandable Valves with Stent Design, Resilient Balloon-Expandable Valves
3) By Mechanically Expanded Transcatheter Aortic Valves: Manually Expanded Valves, Mechanically Operated Valve Systems

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12031&type=smp

Who Are the Global Leaders in the Transcatheter Aortic Valve Replacement Market?
Major companies operating in the transcatheter aortic valve replacement market include Abbott Laboratories Inc., Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, LivaNova PLC, Meril Life Sciences Pvt. Ltd., Venus MedTech HangZhou Inc, Braile Biomedica, Peijia Medical Limited, Direct Flow Medical Inc., Transcatheter Technologies GmbH, Symetis SA, JenaValve Technology Inc., Micro Interventional Devices Inc., Xeltis BV, Tendyne Holdings Inc., MVRx Inc., Keystone Heart Ltd., Colibri Heart Valve LLC, HighLife SAS, Neovasc Inc., Aegis Surgical Limited, Foldax Inc., MValve Technologies Ltd., NaviGate Cardiac Structures Inc.

Which are the Top Profitable Regional Markets for the Transcatheter Aortic Valve Replacement Industry?
North America was the largest region in the transcatheter aortic valve replacement market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transcatheter aortic valve replacement market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12031

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.